| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
-Receptor I (CD89) Recruits Neutrophils as Effector Cells for CD20-Directed Antibody Therapy1
*
Division of Hematology/Oncology, Department of Medicine III, University of Erlangen-Nürnberg, Erlangen, Germany;
Medarex, Annandale, NJ;
Tenovus Research Laboratory, Southampton, U.K.; and
Department of Immunology and Medarex Europe BV, University Hospital Utrecht, Utrecht, The Netherlands
CD20 Abs induce clinical responses in lymphoma patients, but there
are considerable differences between individual patients. In
51Cr release assays with whole blood as effector source,
RAJI cells were effectively killed by a mouse/human chimeric IgG1
construct of CD20 Ab 1F5, whereas ARH-77 proved resistant to killing by
this Ab. When whole blood was fractionated into plasma, mononuclear
cells, or granulocytic effector cells, RAJI cells were effectively
killed in the presence of complement-containing plasma, whereas the
mature B cell line ARH-77 proved complement resistant. However, with a
bispecific Ab (BsAb) against the myeloid receptor for IgA (CD89;
Fc
RI) and CD20, a broad range of B cell lines were effectively
killed. FcRI is expressed on monocytes/macrophages, neutrophils, and
eosinophils. As the numbers of these effector cells and their
functional activity can be enhanced by application of G-CSF or GM-CSF,
lysis via (FcRI x CD20) BsAb was significantly enhanced in
blood from patients during therapy with these myeloid growth factors.
Interestingly, the major effector cell population for this BsAb were
polymorphonuclear neutrophils, which proved ineffective in killing
malignant B cells with murine, chimeric IgG1, or Fc
RI- or
FcRIII-directed BsAbs against CD20. Experiments with blood from
human FcRI/FcRI double-transgenic mice showed corresponding
results, allowing the establishment of relevant syngenic animal models
in these mice. In conclusion, the combination of myeloid growth factors
and an (FcRI x CD20) BsAb may represent a promising approach
to improve effector cell recruitment for CD20-directed lymphoma
therapy.
This article has been cited by other articles:
|
|
 |
|
  M. Duval, M. R. Posner, and L. A. Cavacini A Bispecific Antibody Composed of a Nonneutralizing Antibody to the gp41 Immunodominant Region and an Anti-CD89 Antibody Directs Broad Human Immunodeficiency Virus Destruction by Neutrophils J. Virol., May 1, 2008; 82(9): 4671 - 4674. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. N. Karagiannis, M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. Fear, R. G. Thompson, N. East, F. Burke, et al. IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells J. Immunol., September 1, 2007; 179(5): 2832 - 2843. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dechant, T. Beyer, T. Schneider-Merck, W. Weisner, M. Peipp, J. G. J. van de Winkel, and T. Valerius Effector Mechanisms of Recombinant IgA Antibodies against Epidermal Growth Factor Receptor J. Immunol., September 1, 2007; 179(5): 2936 - 2943. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Horner, C. Frank, C. Dechant, R. Repp, M. Glennie, M. Herrmann, and B. Stockmeyer Intimate Cell Conjugate Formation and Exchange of Membrane Lipids Precede Apoptosis Induction in Target Cells during Antibody-Dependent, Granulocyte-Mediated Cytotoxicity J. Immunol., July 1, 2007; 179(1): 337 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. E. Bakema, S. de Haij, C. F. den Hartog-Jager, J. Bakker, G. Vidarsson, M. van Egmond, J. G. J. van de Winkel, and J. H. W. Leusen Signaling through Mutants of the IgA Receptor CD89 and Consequences for Fc Receptor {gamma}-Chain Interaction J. Immunol., March 15, 2006; 176(6): 3603 - 3610. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E A Clark and J A Ledbetter How does B cell depletion therapy work, and how can it be improved? Ann Rheum Dis, November 1, 2005; 64(suppl_4): iv77 - iv80. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Otten, E. Rudolph, M. Dechant, C. W. Tuk, R. M. Reijmers, R. H. J. Beelen, J. G. J. van de Winkel, and M. van Egmond Immature Neutrophils Mediate Tumor Cell Killing via IgA but Not IgG Fc Receptors J. Immunol., May 1, 2005; 174(9): 5472 - 5480. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Niitsu, M. Khori, M. Hayama, K. Kajiwara, M. Higashihara, and J.-i. Tamaru Phase I/II Study of the Rituximab-EPOCT Regimen in Combination with Granulocyte Colony-Stimulating Factor in Patients with Relapsed or Refractory Follicular Lymphoma Including Evaluation of Its Cardiotoxicity Using B-Type Natriuretic Peptide and Troponin T Levels Clin. Cancer Res., January 15, 2005; 11(2): 697 - 702. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Pasquier, Y. Lepelletier, C. Baude, O. Hermine, and R. C. Monteiro Differential expression and function of IgA receptors (CD89 and CD71) during maturation of dendritic cells J. Leukoc. Biol., December 1, 2004; 76(6): 1134 - 1141. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. D. Kennedy, P. V. Beum, M. D. Solga, D. J. DiLillo, M. A. Lindorfer, C. E. Hess, J. J. Densmore, M. E. Williams, and R. P. Taylor Rituximab Infusion Promotes Rapid Complement Depletion and Acute CD20 Loss in Chronic Lymphocytic Leukemia J. Immunol., March 1, 2004; 172(5): 3280 - 3288. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Stockmeyer, T. Beyer, W. Neuhuber, R. Repp, J. R. Kalden, T. Valerius, and M. Herrmann Polymorphonuclear Granulocytes Induce Antibody-Dependent Apoptosis in Human Breast Cancer Cells J. Immunol., November 15, 2003; 171(10): 5124 - 5129. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Kennedy, M. D. Solga, T. A. Schuman, A. W. Chi, M. A. Lindorfer, W. M. Sutherland, P. L. Foley, and R. P. Taylor An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab Blood, February 1, 2003; 101(3): 1071 - 1079. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Dechant, G. Vidarsson, B. Stockmeyer, R. Repp, M. J. Glennie, M. Gramatzki, J. G. J. van de Winkel, and T. Valerius Chimeric IgA antibodies against HLA class II effectively trigger lymphoma cell killing Blood, December 15, 2002; 100(13): 4574 - 4580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Itoh, T. Ohtsu, H. Fukuda, Y. Sasaki, M. Ogura, Y. Morishima, T. Chou, K. Aikawa, N. Uike, F. Mizorogi, et al. Randomized phase II study of biweekly CHOP and dose-escalated CHOP with prophylactic use of lenograstim (glycosylated G-CSF) in aggressive non-Hodgkin's lymphoma: Japan Clinical Oncology Group Study 9505 Ann. Onc., September 1, 2002; 13(9): 1347 - 1355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Tiroch, B. Stockmeyer, C. Frank, and T. Valerius Intracellular Domains of Target Antigens Influence Their Capacity to Trigger Antibody-Dependent Cell-Mediated Cytotoxicity J. Immunol., April 1, 2002; 168(7): 3275 - 3282. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. van Egmond, A. B. van Spriel, H. Vermeulen, G. Huls, E. van Garderen, and J. G. J. van de Winkel Enhancement of Polymorphonuclear Cell-mediated Tumor Cell Killing on Simultaneous Engagement of Fc{{gamma}}RI (CD64) and Fc{{alpha}}RI (CD89) Cancer Res., May 1, 2001; 61(10): 4055 - 4060. [Abstract] [Full Text]
|
|
|
|
|
|
A. B. van Spriel, J. H. W. Leusen, M. van Egmond, H. B. P. M. Dijkman, K. J. M. Assmann, T. N. Mayadas, and J. G. J. van de Winkel Mac-1 (CD11b/CD18) is essential for Fc receptor-mediated neutrophil cytotoxicity and immunologic synapse formation Blood, April 15, 2001; 97(8): 2478 - 2486. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
